Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.39 |
| ▸ | CCKAR | P32238 | 2/20 | 0.36 |
| ▸ | CCKBR | P32239 | 2/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71225 | 0.98 | GLP1R (0.56) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL15871523 | 0.94 | GLP1R (0.55) | GLP1RSELPNOD1SMN1; SMN2 | |
| SCHEMBL71221 | 0.93 | GLP1R (0.61) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL19261638 | 0.93 | GLP1R (0.61) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL13184775 | 0.92 | GLP1R (0.57) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL15002746 | 0.90 | GLP1R (0.56) | GLP1RSELPNOD1SMN1; SMN2 | |
| SCHEMBL15002721 | 0.89 | GLP1R (0.57) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL14478727 | 0.89 | GLP1R (0.56) | GLP1RSELPNOD1 | |
| SCHEMBL17131127 | 0.89 | GLP1R (0.54) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL20034257 | 0.89 | GLP1R (0.55) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | GLP1R 1/4885SELP 1046/4885NOD1 933/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885SELP 1274/4885NOD1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.